TERPENOIDS - Ibrexafungerp
Mechanism of Action:
Ibrexafungerp inhibits beta-1,3-D-glucan synthase, the enzyme responsible for the production of beta-1,3-D- glucan, via a similar mechanism to the echinocandins. (same target as the echinocandins).
ibrexafungerp is approved only for vulvovaginal candidiasis (a condition for which many other topical and oral antifungal therapies are available).
Adverse Effects
gastrointestinal adverse effects were the primary toxicity noted.